KZIA

AI Memo

Kazia Therapeutics

As of 2026-10-02/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

—

Key catalyst

First patient in HR+/HER2- breast-cancer expansion • 2026-12-31

Base target: $9 / p=45% prob

Biggest risk

Clinical benefit remains unproven across the new indications. The FDA previously told Kazia that existing glioblastoma data were insufficient for an NDA and recommended additional clinical evidence. [#SEC-20F-2025] Kazia annual filing

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The completed offering provides approximately $40 million in upfront gross proceeds for development, while trial execution and later efficacy data could strengthen the paxalisib case. The additional roughly $80 million described in the offering depends on warrant exercise and is not secured cash. [#PR-2026-08-31] Company closing announcement

Research note

Recommendation

—

Confidence

low

As of

2026-10-02

Base target

p=45%

Bull target

$18

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Stage IV TNBC clinical readout
The completed offering provides approximately $40 million in upfront gross proceeds for development, while trial execution and later efficacy data could strengthen the paxalisib case.
The additional roughly $80 million described in the offering depends on warrant exercise and is not secured cash.

BearKey bullets

The FDA's stated need for additional glioblastoma evidence leaves the registrational path unresolved.
[#SEC-20F-2025] Kazia annual filing
The HR+/HER2- and colorectal-cancer expansion cases rely substantially on preclinical evidence; enrollment delays, safety findings or weak patient outcomes could undermine them.

WatchKey bullets

First patient in HR+/HER2- breast-cancer expansion

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +100% / -56%

Scenario probabilities

Bull Target: $18 (p=20%)Base Target: $9 (p=45%)Bear Target: $4 (p=35%)

Commentary

Primary-source updates confirm financing and trial plans, but the packet provides little independent coverage and no usable social or analyst-revision evidence. The zero sentiment-field values indicate unavailable measurements, not neutral observations. The deterministic prior is negative with high uncertainty; this remains a low-conviction monitoring view.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Stage IV TNBC clinical readout

Scenarios

Bull Target (Scenario probability)

$18 / p=20% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$4 / p=35% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
First patient in HR+/HER2- breast-cancer expansion
Kazia expects to enroll the first patient by year-end 2026 in a three-arm paxalisib trial expansion. Enrollment would confirm execution, not clinical efficacy. [#PR-2026-09-01] SEC-filed company release
Prob 60.00% • Move 10.00% • Priced-in 45.00%
EVENT2027-03-31
Planned colorectal-cancer Phase 2 enrollment
Following preclinical results, Kazia plans to begin enrollment in a five-arm paxalisib study in MSS/pMMR colorectal cancer in Q1 2027. The proposed study has not yet established patient benefit. [#PR-2026-09-01-CRC] SEC-filed company release
Prob 50.00% • Move 12.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Stage IV TNBC clinical readout
2027-12-31
The company expects a Stage IV triple-negative breast-cancer readout in the second half of 2027. This is a more consequential efficacy test than trial activation, but timing and results remain uncertain. [#PR-2026-08-28] SEC-filed company release
Prob 45% • Move 45% • Priced-in 25%

Risks

The FDA's stated need for additional glioblastoma evidence leaves the registrational path unresolved. [#SEC-20F-2025] Kazia annual filing
The HR+/HER2- and colorectal-cancer expansion cases rely substantially on preclinical evidence; enrollment delays, safety findings or weak patient outcomes could undermine them. SEC-filed HR+/HER2- release SEC-filed colorectal-cancer release
The roughly $80 million of potential additional offering proceeds requires warrant exercise; the completed upfront raise also increases the ADS count. [#PR-2026-08-31] Company closing announcement

Peers

Symbol	Summary
BDTX	Packet-selected, similar-market-cap biotech comparator; indication and development-stage comparability are unverified.
COYA	Packet-selected, similar-market-cap therapeutic developer; useful for financing-risk context, not a direct paxalisib valuation peer.
RANI	Packet-selected, similar-market-cap biotech; a loose event-risk comparator rather than a mechanism-matched peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

BDTX

Packet-selected, similar-market-cap biotech comparator; indication and development-stage comparability are unverified.

COYA

Packet-selected, similar-market-cap therapeutic developer; useful for financing-risk context, not a direct paxalisib valuation peer.

RANI

Packet-selected, similar-market-cap biotech; a loose event-risk comparator rather than a mechanism-matched peer.